Amycretin is an investigational obesity drug from Novo Nordisk that combines two appetite-regulating mechanisms, GLP-1 and amylin, in a single molecule, and it comes in two forms: a once-daily pill and a once-weekly injection. In early trials, it produced encouraging weight loss, with the subcutaneous version reaching the low 20s percent range at 36 weeks and the oral version producing about 13% at just 12 weeks, both without leveling off by the end of the studies. As of mid-2026, amycretin is early in development and not FDA approved. Novo Nordisk is moving both forms into phase 3 trials in 2026, so it’s a name to watch rather than an option available now.<\/p>\n
Most weight-loss drugs in development combine two or three separate hormone actions. Amycretin’s twist is that it’s a single molecule (unimolecular) that acts on both the GLP-1 and amylin receptors at once.<\/p>\n
GLP-1 reduces appetite, slows stomach emptying, and improves blood sugar handling. Amylin is a hormone released with insulin that promotes fullness and helps regulate food intake. Combining both in one molecule aims to produce strong weight loss, potentially with good tolerability, which is a key goal since side effects are a major reason people stop treatment.<\/p>\n
The other standout feature is flexibility. Amycretin is being developed as both a daily pill and a weekly injection, which could let treatment be tailored to what a person prefers.<\/p>\n
Amycretin’s early evidence comes from two studies. The injectable version was evaluated in a phase 1b\/2a trial published in The Lancet in 2025<\/a>, which found significant weight loss across the doses tested in 125 adults with overweight or obesity, with no plateau by the end. A companion phase 1 trial of the oral form reported about 13% weight loss at 12 weeks, which outpaced what semaglutide produces at the same early timepoint.<\/p>\n It’s important to keep these results in perspective. These were small, early-phase trials, so the figures should be read as promising signals rather than final numbers. Larger phase 3 trials will show what amycretin can really do over longer durations.<\/p>\n